Ionis Pharmaceuticals (IONS) Gross Profit (2018 - 2026)

Ionis Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $243.1 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 86.79% year-over-year to $243.1 million in Q1 2026; TTM through Mar 2026 was $590.7 million, a 16.42% decrease from a year earlier, with the FY2025 full-year figure at $927.8 million, up 33.7% from the prior year.
• Gross Profit grew to $243.1 million in Q1 2026 per IONS's latest filing, from $195.4 million in the prior quarter.
• Across five years, Gross Profit topped out at $321.4 million in Q4 2023 and bottomed at -$2.2 million in Q2 2025.
• The 5-year median for Gross Profit is $148.2 million (2022), against an average of $162.7 million.
• Across the five-year window, Gross Profit soared 116.89% in 2023 and plunged 100.97% in 2025, its largest moves.
• Year by year, Gross Profit stood at $148.2 million in 2022, then soared by 116.89% to $321.4 million in 2023, then tumbled by 30.7% to $222.7 million in 2024, then declined by 12.29% to $195.4 million in 2025, then increased by 24.43% to $243.1 million in 2026.
• Per Business Quant, the three latest IONS Gross Profit figures stand at $243.1 million (Q1 2026), $195.4 million (Q4 2025), and $154.4 million (Q3 2025).